Target- |
Mechanism- |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
顺气痛泻颗粒治疗肠易激综合征肝脾不和证随机、 双盲、安慰剂对照、多中心临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical study on Shunqi Tongxie granules in the treatment of liver-spleen disharmony in irritable bowel syndrome
进一步客观评价顺气痛泻颗粒治疗肠易激综合征腹泻型(肝脾不和证)的有效性及安全性。
[Translation] To further objectively evaluate the effectiveness and safety of Shunqi Tongxie Granules in the treatment of diarrhea type (liver and spleen disharmony syndrome) of irritable bowel syndrome.
顺气痛泻颗粒治疗肠易激综合征腹泻型(肝脾不和证)有效性和安全性的多中心临床研究
[Translation] A multicenter clinical study on the efficacy and safety of Shunqi Tongxie granules in the treatment of irritable bowel syndrome with diarrhea (liver-spleen disharmony syndrome)
探索顺气痛泻颗粒的有效剂量,客观评价顺气痛泻颗粒治疗肠易激综合征腹泻型(肝脾不和证)的有效性及安全性 1、评价顺气痛泻颗粒治疗肠易激综合征(肝脾不和证)的有效性和安全性。 2、探索顺气痛泻颗粒治疗肠易激综合征(肝脾不和证)的有效剂量。
[Translation] To explore the effective dose of Shunqi Tongxie Granules and objectively evaluate the effectiveness and safety of Shunqi Tongxie Granules in treating irritable bowel syndrome (liver-spleen disharmony syndrome) 1. Evaluate the effectiveness and safety of Shunqi Tongxie Granules in treating irritable bowel syndrome (liver-spleen disharmony syndrome). 2. Explore the effective dose of Shunqi Tongxie Granules in treating irritable bowel syndrome (liver-spleen disharmony syndrome).
100 Clinical Results associated with Shanghai Hanlong Medical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Hanlong Medical Technology Co., Ltd.
100 Deals associated with Shanghai Hanlong Medical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Hanlong Medical Technology Co., Ltd.